Kevin C Oboyle
CIK 1203567 · CFO and Executive VP · last filed 2026-06-22
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
NUVA price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
CARLSBAD, CA 92008
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| CARL | Director | 31,031 | $15.10 | $468.6K | $0 | 2 | 2026-06-22 |
| OM | Director | 34,785 | $4.11 | $143.1K | $0 | 3 | 2026-06-05 |
| IRTC | Director | 3,608 | $120.83 | $436.0K | $0 | 2 | 2026-05-29 |
| NEVRO CORP (NVRO) Delisted | Director | 0 | $5.84 | $0 | $301.6K | 10 | 2025-04-03 |
| Sientra, Inc. (SIEN) Delisted | Director | 22,098 | $0.17 | $3.8K | $150.0K | 10 | 2022-06-13 |
| GenMark Diagnostics, Inc. (GNMK) Delisted | Director | 0 | $24.04 | $0 | $3.5K | 19 | 2021-04-22 |
| Wright Medical Group N.V. (WMGI) Delisted | Director | 16,306 | — | — | $0 | 1 | 2019-07-30 |
| Wright Medical Group N.V. (WMGIZ) Delisted | Director | 12,390 | — | — | -$1.82M | 7 | 2019-03-05 |
| Zeltiq Aesthetics Inc (ZLTQ) Delisted | Director | 0 | — | — | -$2.40M | 17 | 2017-04-28 |
| Wright Medical Group N.V. (WMGI.Z) Delisted | Director | 17,053 | — | — | $0 | 4 | 2016-10-17 |
| Wright Medical Group N.V. (TRNX) Delisted | Director | 1 | — | — | $0 | 14 | 2015-08-14 |
| Durata Therapeutics, Inc. (DRTX) Delisted | Director | 0 | — | — | $0 | 2 | 2014-11-18 |
| NUVASIVE INC (NUVA) Delisted | CFO and Executive VP | 46,315 | $39.75 | $1.84M | -$10.49M | 37 | 2009-12-17 |
Recent Filings · Page 2 of 13
129 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2022-06-13 | Sientra, Inc. (SIEN) Delisted | Grant (A) | +103,306 | $0 | EDGAR |
| 2022-05-27 | NEVRO CORP (NVRO) Delisted | Grant (A) | +4,155 | $0 | EDGAR |
| 2021-12-16 | NEVRO CORP (NVRO) Delisted | Buy (P) | +2,400 | $201.1K | EDGAR |
| 2021-06-15 | Sientra, Inc. (SIEN) Delisted | Grant (A) | +16,870 | $0 | EDGAR |
| 2021-05-26 | NEVRO CORP (NVRO) Delisted | Grant (A) | +1,167 | $0 | EDGAR |
| 2021-04-22 | GenMark Diagnostics, Inc. (GNMK) Delisted | Mixed | −131,678 | -$3.17M | EDGAR |
| 2021-02-19 | GenMark Diagnostics, Inc. (GNMK) Delisted | Grant (A) | +10,130 | $0 | EDGAR |
| 2020-11-13 | — | Mixed | −16,306 | -$501.4K | |
| 2020-06-09 | Sientra, Inc. (SIEN) Delisted | Grant (A) | +27,717 | $0 | EDGAR |
| 2020-06-02 | GenMark Diagnostics, Inc. (GNMK) Delisted | Grant (A) | +17,998 | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.